Responsive Playbooks and the AXSM Inflection
This article from Stock Traders Daily discusses Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting divergent sentiment across various time horizons and suggesting choppy market conditions. It presents detailed AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis. The analysis points to an exceptional risk-reward short setup for the stock.
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves
Axsome Therapeutics has initiated a Phase 3 trial for solriamfetol in adolescent ADHD and seen its stock move from small-cap to larger-cap indices, affecting its investment profile. While these developments broaden Axsome's platform, the company's profitability hinges on the successful execution of its existing CNS portfolio and management of high R&D and commercial expenses. The article emphasizes that investors must weigh promising new indications against ongoing net losses and pricing pressures.
HB Wealth Management LLC Grows Holdings in Axsome Therapeutics, Inc. $AXSM
HB Wealth Management LLC significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 47.3% in Q1, now owning 50,237 shares valued at $8.49 million. This occurred despite Axsome missing EPS estimates in its latest quarterly report, with revenue of $191.2 million against an EPS of -$1.26. Analysts maintain a largely bullish outlook on AXSM, with an average rating of "Moderate Buy" and a price target of $258.95.
ETFs Investing in Axsome Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Axsome Therapeutics, Inc. It provides detailed financial information for each ETF, including market value, weight of Axsome Therapeutics in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies, from passive total market funds to specialized healthcare and biotechnology funds.
SG Americas Securities LLC Has $1.25 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM
SG Americas Securities LLC significantly reduced its stake in Axsome Therapeutics by 58.2% in Q1 2026, now holding 7,392 shares valued at $1.25 million. Despite this, Wall Street analysts maintain a "Moderate Buy" rating with an average target price of $258.95. Axsome Therapeutics reported a Q1 loss of $1.26 per share, missing estimates, although revenue increased by 57.4% year-over-year.
Axsome wins FDA label expansion for Auvelity in Alzheimer’s agitation
Axsome Therapeutics has received FDA approval to expand the label for its antidepressant Auvelity, allowing it to be prescribed for the treatment of agitation in patients with Alzheimer's disease. This approval is based on positive results from the Phase 3 ACCORD trial, where Auvelity demonstrated significant improvements in patient agitation compared to placebo. The drug is already marketed for major depressive disorder and this label expansion significantly broadens its potential patient population and market.
Axsome Therapeutics (AXSM) Stock Looks Reasonable On Sales But Stretched After 279% Run
Axsome Therapeutics (AXSM) has seen a significant 279.2% return over the past five years, making its current valuation appear fair rather than cheap. The stock trades at a P/S ratio of 17.5x, which is higher than the industry average, yet Simply Wall St's tailored fair P/S ratio of 18.2x suggests it's appropriately priced. While the launch of the FOCUS-3 Phase 3 trial for solriamfetol offers growth potential, the market seems to have already factored in much of this optimism, leaving investors to weigh continued growth against the current, slightly stretched valuation.
Axsome Therapeutics (AXSM) CEO sells 49,666 exercised shares under 10b5-1 plan
Axsome Therapeutics CEO Herriot Tabuteau exercised 49,666 stock options nearing expiration at a strike price of $4.95 and sold the corresponding shares at a weighted average price of $240.25 under a Rule 10b5-1 trading plan. After these transactions, he directly holds 7,229 common shares and indirectly holds 7,344,500 shares through an entity. The sale was a routine, pre-planned event necessitated by the options' 10-year expiration date.
49,666-share sale notice for AXSM (NASDAQ: AXSM) via cashless exercise
Axsome Therapeutics, Inc. (NASDAQ: AXSM) filed a Form 144, indicating a proposed sale of 49,666 shares of common stock. These shares were acquired as compensation via stock options and are planned to be sold through a cashless exercise/same-day sale facilitated by Goldman Sachs & Co. LLC. The filing also notes prior sales by Herriot Tabuteau of 24,835 shares on June 9, 2026.
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism?
Axsome Therapeutics Inc. (AXSM) saw its stock rise more than 10% after analysts from Jefferies, Deutsche Bank, and H.C. Wainwright raised their price targets and maintained "Buy" ratings, despite the company reporting mixed Q1 results. The optimism largely stems from the strong Q1 sales of Auvelity, Axsome’s treatment for major depressive disorder and Alzheimer’s agitation, which exceeded consensus estimates and recently received a "clean label" FDA approval for Alzheimer's. Analysts anticipate considerable growth for Auvelity, especially with a potential label expansion and the commercial launch for Alzheimer's agitation slated for June, supported by an expanded sales force.
Pictet Asset Management Holding SA Sells 20,080 Shares of Axsome Therapeutics, Inc. $AXSM
Pictet Asset Management Holding SA reduced its stake in Axsome Therapeutics, Inc. by 4.6% in the first quarter, selling 20,080 shares and retaining 415,983 shares valued at approximately $70.3 million. Despite Axsome missing EPS estimates for its latest earnings report, Wall Street analysts maintain a "Moderate Buy" rating with an average target price of $258.95. Meanwhile, other institutional investors have modified their holdings, and company insiders have recently sold shares.
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet
The Sleep Apnea market is projected to reach USD 5,681 million by 2034, growing at a CAGR of 27% from an estimated USD 661 million in 2025, driven by increasing prevalence, awareness, and pipeline product launches. Key companies like Eli Lilly, Apnimed, and Incannex Healthcare are developing advanced therapies, including metabolic treatments and hypoglossal nerve stimulation systems. Despite barriers like underdiagnosis and adherence issues, new drug approvals and technological advancements are expected to revolutionize treatment options for obstructive and central sleep apnea.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Is Expected To Breakeven In The Near Future
This article analyzes Axsome Therapeutics (NASDAQ:AXSM) and projects its path to profitability. It details the company's expected breakeven point based on analyst forecasts and discusses the factors influencing its financial performance. The report also touches upon stock price performance and insider transactions.
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Index
Axsome Therapeutics, Inc. (NasdaqGM: AXSM) has been removed from the Russell 2000 Index. The biopharmaceutical company focuses on developing medicines for central nervous system conditions, with commercial products including AUVELITY, SUNOSI, and SYMBRAVO, and a pipeline of novel product candidates. This news follows recent company updates such as presentations at healthcare conferences, patent dispute settlements, and analyst rating adjustments.
Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) has been removed from the Russell 2000 Growth Benchmark. The biopharmaceutical company focuses on developing medicines for Central Nervous System (CNS) conditions, with commercial products including AUVELITY, SUNOSI, and SYMBRAVO. Analysts generally have a "BUY" consensus for AXSM, with an average target price of $276.47, indicating a potential increase of 14.40% from its last close price of $241.67.
Axsome Therapeutics (AXSM) Rallied On Growth Hopes, Is The Upside Already Priced In?
Axsome Therapeutics (AXSM) has seen significant share price appreciation and is considered 12.6% undervalued with a fair value estimate of $276.47, driven by its late-stage clinical programs. However, its current P/S ratio of 17.6x is much higher than the industry average, indicating potential valuation risk despite growth prospects. The company faces challenges including reliance on key products and continued net losses.
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Dynamic Index
Axsome Therapeutics, Inc. (NasdaqGM: AXSM) has been removed from the Russell 2000 Dynamic Index. The biopharmaceutical company focuses on developing medicines for central nervous system conditions, with commercial products including AUVELITY, SUNOSI, and SYMBRAVO, and a pipeline of novel product candidates. Analysts currently have a mean consensus of "BUY" for AXSM, with an average target price of $276.47, indicating a potential spread of +14.40% from its last close price of $241.67.
Price to sales forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM
This article provides a brief financial data point for Axsome Therapeutics, Inc. (NASDAQ: AXSM), specifically its "Price to sales forward" metric. The content itself seems to be an excerpt from a larger financial data platform, indicating information about the company's valuation.
Price to earnings forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM
This article provides access to the "Price to earnings forward" metric for Axsome Therapeutics, Inc. (NASDAQ: AXSM) on the TradingView platform. It highlights the availability of financial data for the company and directs users to TradingView's market analysis tools.
Price to earnings forward of Axsome Therapeutics, Inc. – LSX:A2AA7B
This page from TradingView provides financial information for Axsome Therapeutics, Inc. (LSX:A2AA7B), specifically focusing on its forward price-to-earnings ratio. The article includes metadata about the stock and highlights that no trades have occurred, with the market currently closed. It also mentions data sources like ICE Data Services and FactSet.
Is Axsome Therapeutics (AXSM) Using Solriamfetol’s Phase 3 ADHD Trial To Redefine Its CNS Strategy?
Axsome Therapeutics has initiated a Phase 3 trial (FOCUS-3) for solriamfetol in adolescents with ADHD, expanding its CNS treatment portfolio beyond sleep conditions. This move aims to diversify Axsome's investment narrative, although the company still faces challenges with net losses and a finite cash runway. The recent settlement of SUNOSI patent litigation, pushing generic entry to 2040, provides a clearer economic window for solriamfetol's future indications.
Axsome doses first patient in phase 3 ADHD trial
Axsome Therapeutics has initiated its FOCUS-3 Phase 3 trial for solriamfetol in adolescents with ADHD, a randomized, double-blind, placebo-controlled study involving approximately 468 patients. The drug, a dopamine and norepinephrine reuptake inhibitor, is also being developed for other conditions like major depressive disorder and binge eating disorder. Despite not yet being profitable, the company, valued at $12.2 billion, has shown a 131% return over the past year and analyst firms have raised price targets based on potential sales and pipeline developments.
Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.
Axsome Therapeutics has commenced the FOCUS-3 Phase 3 clinical trial to assess solriamfetol as a treatment for ADHD in adolescents aged 12 to under 18. This six-week, randomized, double-blind, placebo-controlled study will involve approximately 468 patients to evaluate the drug's efficacy and safety. The trial aims to address unmet needs in adolescent ADHD care and potentially provide a new treatment option for the condition.
What's Driving Axsome Therapeutics' Recent Bull Run
Axsome Therapeutics (AXSM) has experienced a significant stock rally due to strong revenue growth and key advancements in its neuroscience pipeline, notably the priority review for AXS-05 for Alzheimer's disease agitation. The potential approval of AXS-05, with a PDUFA date of April 30, 2026, represents a multi-billion dollar market opportunity, poised to diversify the company's revenue and impact its valuation. While analysts are optimistic, investors should consider the inherent risks associated with biotech regulatory approvals, commercialization hurdles, and Axsome's current unprofitability.
Axsome Therapeutics doses first patient in FOCUS-3 phase 3 ADHD trial
Axsome Therapeutics has dosed the first patient in its FOCUS-3 Phase 3 trial for solriamfetol, aimed at treating ADHD in adolescents. This randomized, double-blind study will enroll approximately 468 patients aged 12 to 18 to evaluate the drug's efficacy over six weeks. The trial expands the potential uses of solriamfetol, which is currently approved for excessive daytime sleepiness related to narcolepsy or sleep apnea in adults.
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics has initiated the FOCUS-3 Phase 3 trial for solriamfetol in adolescents aged 12 to under 18 years with Attention Deficit Hyperactivity Disorder (ADHD). The trial will evaluate the efficacy and safety of solriamfetol in approximately 468 patients, with the primary endpoint being the change in ADHD-RS-5 total score. Solriamfetol is a dopamine and norepinephrine reuptake inhibitor also being developed for other CNS disorders.
Axsome starts 468-patient ADHD trial for teens
Axsome Therapeutics has initiated its FOCUS-3 Phase 3 trial for solriamfetol, aimed at treating adolescents aged 12 to under 18 with Attention Deficit Hyperactivity Disorder (ADHD). This randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 468 patients to assess the efficacy and safety of solriamfetol over a 6-week period, with the primary endpoint being the change in ADHD-RS-5 total score. This move expands Axsome's CNS pipeline, bringing a new potential treatment option for the millions affected by ADHD.
Price to book forward of Axsome Therapeutics, Inc. – LSE:0HKF
This page displays the "Price to book forward" financial metric for Axsome Therapeutics, Inc. (LSE:0HKF). It provides market data and financial information for the company, accessible through TradingView. The page indicates that the market is currently closed with no trades recorded.
Axsome Therapeutics, Inc. Actuals & Estimates (NASDAQ:AXSM)
This article provides an overview of Axsome Therapeutics, Inc. (NASDAQ:AXSM) financials, stock performance, and analyst forecasts. It covers current stock price, market capitalization, historical highs and lows, volatility, and upcoming earnings dates, alongside past earnings and revenue figures.
Axsome Therapeutics, Inc. Actuals & Estimates (FWB:19X)
This article provides an overview of Axsome Therapeutics, Inc. (FWB:19X) stock performance, financial data, and analyst forecasts. It covers information such as current stock price, historical highs and lows, market capitalization, volatility, earnings reports, revenue, net income, EBITDA, and employee count. The article also includes analysts' price targets and recommendations, alongside a disclaimer that it is not investment advice.
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – LSE:0HKF
This article provides the enterprise value to EBITDA forward metrics for Axsome Therapeutics, Inc. (LSE:0HKF). It presents financial data for the company, indicating the period, value, and change percentages. The content is primarily a data presentation, typical of financial information platforms like TradingView.
Enterprise value to revenue forward of Axsome Therapeutics, Inc. – LSE:0HKF
This article provides a financial snapshot for Axsome Therapeutics, Inc. (LSE:0HKF) focusing on its enterprise value to revenue forward. It indicates market data and offers various platform tools and community features for investors.
Assenagon Asset Management S.A. Grows Stock Holdings in Axsome Therapeutics, Inc. $AXSM
Assenagon Asset Management S.A. significantly increased its stake in Axsome Therapeutics ($AXSM) by 85% during the first quarter of 2026, acquiring nearly 398,000 additional shares to hold a total of 865,958 shares valued at $146.4 million. Despite the company missing EPS expectations in the first quarter with a loss of $1.26 per share, analysts largely maintain a "Moderate Buy" rating for AXSM, with an average price target of $258.95. Insider selling also occurred during the quarter, with several executives cashing out shares.
Price to earnings forward of Axsome Therapeutics, Inc. – LSE:0HKF
This article provides the "Price to earnings forward" value for Axsome Therapeutics, Inc. (LSE:0HKF). It presents a specific numerical value and its percentage change, noting that the data was made by humans and is available in English. The surrounding content primarily consists of navigation and technical information related to TradingView.
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Leader with 57.4% Revenue Growth and Strong Buy Ratings
Axsome Therapeutics, Inc. (AXSM) is a biotech company focused on CNS disorders, currently experiencing significant market confidence with a $12.89 billion market cap and 57.4% revenue growth, driven by therapies like Auvelity and Sunosi. Despite being unprofitable with negative EPS and ROI, its stock is near a 52-week high, supported by strong technical indicators and overwhelmingly positive analyst ratings with a 10.37% potential upside. The company faces high capital investment and negative free cash flow but offers long-term growth potential for high-risk tolerant investors.
Enterprise value of Axsome Therapeutics, Inc. – XETR:19X
This article provides access to the enterprise value of Axsome Therapeutics, Inc. (XETR:19X) on TradingView. It indicates that the market is currently closed with no trades. The content primarily highlights the financial data section for the company on the platform.
Virtu Financial LLC Invests $2.84 Million in Axsome Therapeutics, Inc. $AXSM
Virtu Financial LLC has acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by purchasing 15,573 shares valued at approximately $2.84 million during the fourth quarter. This move highlights strong institutional interest, with 81.49% of the stock owned by institutions and hedge funds. Despite some recent insider selling, Wall Street analysts maintain a "Moderate Buy" consensus rating for Axsome Therapeutics, with an average target price of $258.95.
12,955 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by Seven Fleet Capital Management LP
Seven Fleet Capital Management LP recently acquired 12,955 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) for approximately $2.37 million, making it their 7th largest holding. This purchase contributes to strong institutional interest, with hedge funds owning 81.49% of the stock. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $258.95.
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics announced new data presentations on its innovative sleep medicine portfolio, specifically AXS-12 and solriamfetol, at the SLEEP 2026 conference. The presentations include findings from the Phase 3 ENCORE trial for AXS-12 in narcolepsy with cataplexy, a post-hoc analysis of solriamfetol's efficacy in narcolepsy and OSA, and a subgroup analysis from the CRESCENDO survey on symptom burden in narcolepsy patients. These data highlight the company's commitment to addressing central nervous system disorders with differentiated products.
Axsome Therapeutics Inc (AXSM) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Axsome Therapeutics Inc (AXSM), listing major institutional shareholders like Antecip Capital, BlackRock, and Vanguard. It also categorizes shareholders by type, including investment advisors, hedge funds, and corporations, and provides a historical overview of institutional holdings and recent shareholder activity. The information highlights the significant institutional interest in AXSM.
Axsome Therapeutics Inc (AXSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a detailed revenue breakdown for Axsome Therapeutics Inc (AXSM) for FY2025, categorizing it by business segments and geographic regions. The company's primary revenue drivers are Auvelity and Sunosi, with the vast majority of its revenue generated within the United States.
Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Axsome Therapeutics Inc.'s (AXSM) dividend and stock split history. It states that the company has distributed no dividends over the past 5 years and has no recorded stock split data. The page also shows current stock performance and market capitalization for AXSM.
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade
Axsome Therapeutics (NASDAQ:AXSM) reached a new 52-week high after TD Cowen increased its price target to $300, maintaining a "buy" rating. Despite strong analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $258.95, insiders have been selling shares, including CEO Herriot Tabuteau. The company, which specializes in CNS disorder therapies, reported mixed Q1 2026 earnings, missing EPS estimates but meeting revenue expectations.
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics is raising awareness for brain health during Alzheimer's & Brain Awareness Month by partnering with advocacy groups and sharing resources. The company emphasizes the importance of everyday habits like physical activity, healthy eating, social connection, and mental challenges in protecting brain health. Alzheimer's disease affects over 7 million individuals in the US, with projections to reach 13 million by 2050, highlighting the urgent need for support and research.
Cormorant Asset Management LP Sells 25,000 Shares of Axsome Therapeutics, Inc. $AXSM
Cormorant Asset Management LP reduced its stake in Axsome Therapeutics by 25% in Q4, selling 25,000 shares and retaining 75,000 shares valued at $13.7 million. Despite insider selling by directors, analyst sentiment remains positive, with a "Moderate Buy" rating and an average price target of $258.95. Axsome reported mixed quarterly results, missing EPS estimates but achieving 57.4% year-over-year revenue growth.
BVF Inc. IL Sells 441,000 Shares of Axsome Therapeutics, Inc. $AXSM
BVF Inc. IL significantly reduced its stake in Axsome Therapeutics, Inc. by selling 441,000 shares in the fourth quarter, retaining 45,757 shares valued at $8.36 million. This follows other insider selling, including CFO Nick Pizzie selling 33,000 shares for $7.9 million. Despite this, analysts maintain a "Moderate Buy" consensus rating with an average price target of $258.95, while the stock recently traded near $252.16 after substantial gains over the past year.
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $300.00 at TD Cowen
TD Cowen has raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $300.00 from $275.00, reiterating a "buy" rating and implying a potential upside of nearly 19%. This positive outlook is echoed by other analysts, contributing to a "Moderate Buy" consensus. Despite strong revenue growth of 57.4% to $191.2 million in the last quarter, the company missed EPS expectations, and several insiders recently sold shares.
Axsome Therapeutics (AXSM) Presented New Phase 3 Sleep Disorder Data That Investors Will Watch
Axsome Therapeutics (AXSM) recently presented new Phase 3 data on AXS-12 for narcolepsy and additional Phase 3/post hoc analyses on solriamfetol for sleep disorders, drawing investor attention. The stock has seen significant returns, and these presentations add fresh context to its central nervous system pipeline. Investors are advised to watch the stock's performance relative to analyst targets and future regulatory milestones for AXS-12 and solriamfetol.
Cynosure Group LLC Sells 4,369 Shares of Axsome Therapeutics, Inc. $AXSM
Cynosure Group LLC significantly reduced its stake in Axsome Therapeutics by selling 4,369 shares, decreasing its holdings by 55.7%. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for AXSM, with an average price target of $256.79. Axsome reported a revenue increase of 57.4% year-over-year to $191.2 million, largely meeting expectations, though it missed EPS estimates.
Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at Truist Financial
Truist Financial has upgraded Axsome Therapeutics (NASDAQ:AXSM) to a "strong-buy" rating, contributing to a generally positive analyst outlook for the company. Despite mixed recent earnings and notable insider selling, the stock maintains a consensus "Moderate Buy" rating with a price target of $256.79. Shares opened near their 52-week high, reflecting strong recent momentum.
